Dosing Begins in Phase 3 Trial of Pfizer’s Gene Therapy for Duchenne

Dosing Begins in Phase 3 Trial of Pfizer’s Gene Therapy for Duchenne

282845

Dosing Begins in Phase 3 Trial of Pfizer’s Gene Therapy for Duchenne

The first boy has been dosed in a Phase 3 trial testing Pfizer‘s gene therapy, PF-06939926, in treating Duchenne muscular dystrophy (DMD). “The initiation of our pivotal trial, which is the first Phase 3 DMD gene therapy program to begin enrolling eligible participants, is an important milestone for the community because there are currently no approved disease-modifying treatment options available for all genetic forms of DMD,” Brenda Cooperstone, MD, chief development officer at Pfizer Global Product Development,…

You must be logged in to read/download the full post.